SOPHiA GENETICS SA (SOPH) Stock Analysis and Metrics

SOPHiA GENETICS

NASDAQ: SOPH

$5.73 ▼ -0.32 (-5.29%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap408.62 Mn

P/E-11.96

P/S5.29

Div. Yield0.00

ROIC (Qtr)-0.02

Total Debt (Qtr)47.73 Mn

Revenue Growth (1y) (Qtr)22.41

Add ratio to table…

About

SOPHiA GENETICS SA is a cloud-native software technology company dedicated to advancing data-driven medicine in healthcare. The company's core product the SOPHiA DDM platform standardizes computes and analyzes digital health data from diverse sources including genomic radiomic and clinical datasets to generate clinically actionable insights. This enables healthcare institutions to break down data silos and build collective intelligence through a decentralized network where customers perform testing on their own samples retain custody of data and share pseudonymized insights globally. The platform supports applications across oncology rare diseases infectious diseases cardiology neurology metabolism and other therapeutic areas to improve diagnosis treatment and drug development.

SOPHiA GENETICS SA generates revenue primarily through access to its SOPHiA DDM platform under three main models: dry lab access where customers use their own sequencing equipment with the platform's analytics bundle access which combines third-party instruments with the platform's solution and integrated access where the company facilitates sequencing through its partner network. The primary pricing strategy for clinical customers is a pay-per-use model with fees applied per analysis performed. Additional revenue streams include the Alamut suite for genomic interpretation and specialized biopharma applications such as SOPHiA Insights for real-world evidence SOPHiA Trial Match for patient recruitment SOPHiA CDx for companion diagnostics and SOPHiA Awareness for market intelligence. Commercialization leverages a direct sales force of over 105 representatives and distributor partners covering 75 countries.

SOPHiA GENETICS SA occupies a leading position as one of the most widely used decentralized analytics platforms for clinical genomics worldwide. The company distinguishes itself through its cloud-native architecture that enables seamless integration with diverse laboratory workflows while ensuring customer data remains under local control. Key competitors encompass integrated diagnostics enterprises such as Roche and specialized players like Tempus Labs alongside genomic software companies including Illumina Agilent and Qiagen. Competitive advantages derive from the scale of its global network which continuously refines its AI algorithms through accumulated real-world data and from its unique capability to support multi-omic analysis combining genomics with radiomics and clinical data to generate deeper disease insights.

As of December 31 2025 SOPHiA GENETICS SA served more than 993 hospital laboratory and biopharmaceutical customers across the globe. The customer base comprises academic and non-academic hospitals including comprehensive cancer centers and children's hospitals reference laboratories specialty laboratories and pharmaceutical biotechnology companies. Through its platform the company has enabled analysis of approximately 2300000 genomic profiles with recent growth of about 33000 new monthly additions. This activity has contributed to over 2712 peer-reviewed publications and supports users in 75 countries via a direct sales team present in 60 nations and distributor partnerships in an additional 50 regions.

Investment Thesis

▲ Bull case

SOPHiA GENETICS is positioned to capitalize on the accelerating shift toward decentralized genomic testing in the U.S., where reimbursement stabilization and declining denial rates are enabling hospitals and labs to bring testing in-house rather than rely on centralized reference labs. This structural shift, highlighted by Ross Muken’s discussion of expanded partnerships with Mount Sinai, NYU Langone, and Memorial Sloan Kettering, creates a durable competitive moat as institutions that adopt SOPHiA DDM face increasing switching costs due to workflow integration, data network effects, and turnaround time advantages. The company’s ability to sign three separate expand deals in Europe each exceeding $1 million in annual contract value demonstrates that customers are not merely adopting the platform but are consolidating their entire genomics strategy around it — a signal of deepening trust and long-term contractual stickiness that the market may be undervaluing given the company’s current enterprise value relative to its recurring revenue base. The virtuous loop of data contribution improving algorithmic accuracy, which in turn drives further adoption, is self-reinforcing and increasingly difficult for competitors to replicate without a comparable global data footprint.
The company’s expansion into multimodal analytics and liquid biopsy applications — particularly MSK Access and MSK Impact — is creating a new high-margin growth vector that remains underappreciated in current guidance. With liquid biopsy analysis growing over 100% year-over-year in Q1 and ASPs trending upward due to higher-value test mix, SOPHiA is transitioning from a commoditized sequencing analytics provider to a clinical decision-support platform with proprietary AI insights. Management’s deliberate focus on expanding within existing accounts — evidenced by net dollar retention rising to 117% from 103% — reveals a land-and-expand strategy that is generating organic growth with minimal incremental sales cost, a dynamic that could sustain double-digit revenue growth even if new customer acquisition slows. Furthermore, the biopharma momentum, including recent signings with AstraZeneca and Johnson & Johnson, is not merely a revenue stream but a strategic enabler: pharma partnerships are feeding real-world evidence generation that enhances the platform’s clinical validity, which in turn strengthens its appeal to hospitals — a flywheel effect that could unlock significant long-term value as companion diagnostics and post-launch monitoring become standard in oncology drug development.
SOPHiA’s path to adjusted EBITDA breakeven by end-2026 and profitability in H2 2027 is more credible than the market perceives, driven by operating leverage from its cloud-native, AI-optimized platform. The company’s adjusted gross margin of 75.4% in Q1 — despite headwinds from Swiss franc strength and litigation costs — reflects the scalability of its core technology, where marginal costs of processing additional genomic analyses are near zero once the platform is scaled. Recent internal AI tool deployments have improved operational efficiency across G&A and R&D functions, allowing reinvestment into high-growth areas without increasing headcount. The $1 million investment in the Swiss lab build-out is a one-time capacity expansion that will support years of revenue growth, not a recurring cost drain. With cash reserves of $65.4 million and an expanded $25 million credit facility, SOPHiA has ample liquidity to weather near-term volatility while executing its profitability roadmap, and the market may be overemphasizing short-term cash burn without recognizing that the underlying unit economics are improving rapidly as volume scales and mix shifts toward higher-ASP tests.

SOPHiA GENETICS is positioned to capitalize on the accelerating shift toward decentralized genomic testing in the U.S., where reimbursement stabilization and declining denial rates are enabling hospitals and labs to bring testing in-house rather than rely on centralized reference labs. This structural shift, highlighted by Ross Muken’s discussion of expanded partnerships with Mount Sinai, NYU Langone, and Memorial Sloan Kettering, creates a durable competitive moat as institutions that adopt SOPHiA DDM face increasing switching costs due to workflow integration, data network effects, and turnaround time advantages. The company’s ability to sign three separate expand deals in Europe each exceeding $1 million in annual contract value demonstrates that customers are not merely adopting the platform but are consolidating their entire genomics strategy around it — a signal of deepening trust and long-term contractual stickiness that the market may be undervaluing given the company’s current enterprise value relative to its recurring revenue base. The virtuous loop of data contribution improving algorithmic accuracy, which in turn drives further adoption, is self-reinforcing and increasingly difficult for competitors to replicate without a comparable global data footprint.
The company’s expansion into multimodal analytics and liquid biopsy applications — particularly MSK Access and MSK Impact — is creating a new high-margin growth vector that remains underappreciated in current guidance. With liquid biopsy analysis growing over 100% year-over-year in Q1 and ASPs trending upward due to higher-value test mix, SOPHiA is transitioning from a commoditized sequencing analytics provider to a clinical decision-support platform with proprietary AI insights. Management’s deliberate focus on expanding within existing accounts — evidenced by net dollar retention rising to 117% from 103% — reveals a land-and-expand strategy that is generating organic growth with minimal incremental sales cost, a dynamic that could sustain double-digit revenue growth even if new customer acquisition slows. Furthermore, the biopharma momentum, including recent signings with AstraZeneca and Johnson & Johnson, is not merely a revenue stream but a strategic enabler: pharma partnerships are feeding real-world evidence generation that enhances the platform’s clinical validity, which in turn strengthens its appeal to hospitals — a flywheel effect that could unlock significant long-term value as companion diagnostics and post-launch monitoring become standard in oncology drug development.
SOPHiA’s path to adjusted EBITDA breakeven by end-2026 and profitability in H2 2027 is more credible than the market perceives, driven by operating leverage from its cloud-native, AI-optimized platform. The company’s adjusted gross margin of 75.4% in Q1 — despite headwinds from Swiss franc strength and litigation costs — reflects the scalability of its core technology, where marginal costs of processing additional genomic analyses are near zero once the platform is scaled. Recent internal AI tool deployments have improved operational efficiency across G&A and R&D functions, allowing reinvestment into high-growth areas without increasing headcount. The $1 million investment in the Swiss lab build-out is a one-time capacity expansion that will support years of revenue growth, not a recurring cost drain. With cash reserves of $65.4 million and an expanded $25 million credit facility, SOPHiA has ample liquidity to weather near-term volatility while executing its profitability roadmap, and the market may be overemphasizing short-term cash burn without recognizing that the underlying unit economics are improving rapidly as volume scales and mix shifts toward higher-ASP tests.

▼ Bear case

SOPHiA GENETICS remains heavily dependent on a narrow set of high-growth applications — particularly liquid biopsy and enhanced exome tests — to drive its revenue acceleration, creating concentration risk if adoption of these specific assays fails to meet expectations across key markets. While liquid biopsy analysis grew over 100% year-over-year in Q1, this growth is coming off a very small base, and the company’s reliance on pharma-driven companion diagnostics (e.g., MSK Access) exposes it to the volatility of drug approval timelines and reimbursement policies that are outside its control. The company’s acknowledgment that Latin America remains soft and requires leadership changes suggests emerging market penetration is more fragile than management implies, and the region’s pharma sensitivity means revenue there could fluctuate significantly based on local drug launches — a risk amplified by macroeconomic instability in key countries like Brazil and Argentina. Furthermore, the company’s guidance for 2026 revenue growth of 20%–22% is heavily back-half weighted, implying that the full-year outcome hinges on successful onboarding of 2025 signings; any delay in implementation due to hospital budget cycles, staff training gaps, or IT integration challenges could leave the company falling short of its targets, especially given its historically conservative guidance approach that may mask underlying execution risks.
The patent litigation with Guardant Health over the MSK Access application presents an ongoing legal and financial overhang that could escalate beyond current expectations, despite the favorable interim ruling from the Unified Patent Court. While SOPHiA recovered $700,000 in interim costs, the company still incurred approximately $700,000 in net litigation expenses in Q1 alone, and the case remains active in both the UK and UPC jurisdictions, with potential for damages, injunctions, or licensing fees that could materially impact gross margins if the platform is forced to alter its technology or pay royalties. Management’s characterization of litigation costs as “lumpy” and confined to the pharma business understates the systemic risk: if Guardant prevails, it could undermine the commercial viability of one of SOPHiA’s flagship, high-ASP applications, triggering a reevaluation of the platform’s value proposition by both clinical and biopharma customers. The legal uncertainty may also deter new biopharma partners from committing to long-term collaborations, particularly as competitors like Illumina and Roche offer more legally secure diagnostic ecosystems, thereby eroding SOPHiA’s differentiated positioning in the companion diagnostics space.
SOPHiA’s claimed network effects and data advantage may be overstated, as the value of its 2.5 million genomic profiles is contingent on data quality, diversity, and clinical annotation — factors that are not uniformly present across its global user base. While the company highlights data from 75 countries, the real-world utility of this data for training AI models is limited if datasets lack standardized phenotypic outcomes, treatment responses, or longitudinal follow-up — critical inputs for developing predictive algorithms in areas like MRD or multimodal analytics. The company’s pivot toward multimodal and real-world evidence generation requires significant investment in data curation, governance, and regulatory compliance, areas where it has limited demonstrated expertise compared to established players like Tempus or Flatiron Health. Moreover, the increasing competition from large tech companies (e.g., Google Health, Microsoft Cloud for Healthcare) and entrenched diagnostics giants entering the AI-genomics space with deeper pockets and broader clinical integration capabilities could commoditize SOPHiA’s core offering, forcing it into a price war it cannot win given its relatively modest scale and lack of proprietary wet-lab infrastructure. Without clear differentiation beyond its current platform, the company risks being perceived as a middleware provider rather than an essential clinical intelligence system, limiting its ability to sustain premium pricing or expand beyond niche oncology applications.

SOPHiA GENETICS remains heavily dependent on a narrow set of high-growth applications — particularly liquid biopsy and enhanced exome tests — to drive its revenue acceleration, creating concentration risk if adoption of these specific assays fails to meet expectations across key markets. While liquid biopsy analysis grew over 100% year-over-year in Q1, this growth is coming off a very small base, and the company’s reliance on pharma-driven companion diagnostics (e.g., MSK Access) exposes it to the volatility of drug approval timelines and reimbursement policies that are outside its control. The company’s acknowledgment that Latin America remains soft and requires leadership changes suggests emerging market penetration is more fragile than management implies, and the region’s pharma sensitivity means revenue there could fluctuate significantly based on local drug launches — a risk amplified by macroeconomic instability in key countries like Brazil and Argentina. Furthermore, the company’s guidance for 2026 revenue growth of 20%–22% is heavily back-half weighted, implying that the full-year outcome hinges on successful onboarding of 2025 signings; any delay in implementation due to hospital budget cycles, staff training gaps, or IT integration challenges could leave the company falling short of its targets, especially given its historically conservative guidance approach that may mask underlying execution risks.
The patent litigation with Guardant Health over the MSK Access application presents an ongoing legal and financial overhang that could escalate beyond current expectations, despite the favorable interim ruling from the Unified Patent Court. While SOPHiA recovered $700,000 in interim costs, the company still incurred approximately $700,000 in net litigation expenses in Q1 alone, and the case remains active in both the UK and UPC jurisdictions, with potential for damages, injunctions, or licensing fees that could materially impact gross margins if the platform is forced to alter its technology or pay royalties. Management’s characterization of litigation costs as “lumpy” and confined to the pharma business understates the systemic risk: if Guardant prevails, it could undermine the commercial viability of one of SOPHiA’s flagship, high-ASP applications, triggering a reevaluation of the platform’s value proposition by both clinical and biopharma customers. The legal uncertainty may also deter new biopharma partners from committing to long-term collaborations, particularly as competitors like Illumina and Roche offer more legally secure diagnostic ecosystems, thereby eroding SOPHiA’s differentiated positioning in the companion diagnostics space.
SOPHiA’s claimed network effects and data advantage may be overstated, as the value of its 2.5 million genomic profiles is contingent on data quality, diversity, and clinical annotation — factors that are not uniformly present across its global user base. While the company highlights data from 75 countries, the real-world utility of this data for training AI models is limited if datasets lack standardized phenotypic outcomes, treatment responses, or longitudinal follow-up — critical inputs for developing predictive algorithms in areas like MRD or multimodal analytics. The company’s pivot toward multimodal and real-world evidence generation requires significant investment in data curation, governance, and regulatory compliance, areas where it has limited demonstrated expertise compared to established players like Tempus or Flatiron Health. Moreover, the increasing competition from large tech companies (e.g., Google Health, Microsoft Cloud for Healthcare) and entrenched diagnostics giants entering the AI-genomics space with deeper pockets and broader clinical integration capabilities could commoditize SOPHiA’s core offering, forcing it into a price war it cannot win given its relatively modest scale and lack of proprietary wet-lab infrastructure. Without clear differentiation beyond its current platform, the company risks being perceived as a middleware provider rather than an essential clinical intelligence system, limiting its ability to sustain premium pricing or expand beyond niche oncology applications.

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password